IS5453A - Samsetning af aldósa redúktasa lata og glýkógen fosfórýlasa lata - Google Patents

Samsetning af aldósa redúktasa lata og glýkógen fosfórýlasa lata

Info

Publication number
IS5453A
IS5453A IS5453A IS5453A IS5453A IS 5453 A IS5453 A IS 5453A IS 5453 A IS5453 A IS 5453A IS 5453 A IS5453 A IS 5453A IS 5453 A IS5453 A IS 5453A
Authority
IS
Iceland
Prior art keywords
inhibitor
composition
aldose reductase
glycogen phosphorylase
reductase inhibitor
Prior art date
Application number
IS5453A
Other languages
English (en)
Inventor
Lakshman Mylari Banavara
Jay Hoover Dennis
Hulin Bernard
Lee Treadway Judith
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS5453A publication Critical patent/IS5453A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Superheterodyne Receivers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Noise Elimination (AREA)
  • Enzymes And Modification Thereof (AREA)
IS5453A 1997-11-21 2000-04-14 Samsetning af aldósa redúktasa lata og glýkógen fosfórýlasa lata IS5453A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6636597P 1997-11-21 1997-11-21
PCT/IB1998/001752 WO1999026659A1 (en) 1997-11-21 1998-11-02 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor

Publications (1)

Publication Number Publication Date
IS5453A true IS5453A (is) 2000-04-14

Family

ID=22069038

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5453A IS5453A (is) 1997-11-21 2000-04-14 Samsetning af aldósa redúktasa lata og glýkógen fosfórýlasa lata

Country Status (38)

Country Link
EP (1) EP1032424B9 (is)
JP (1) JP2002504478A (is)
KR (2) KR20010032304A (is)
CN (1) CN1279617A (is)
AP (1) AP911A (is)
AR (1) AR016423A1 (is)
AT (1) ATE205403T1 (is)
AU (1) AU733304B2 (is)
BG (1) BG104435A (is)
BR (1) BR9814698A (is)
CA (1) CA2310069A1 (is)
DE (1) DE69801680T2 (is)
DK (1) DK1032424T3 (is)
DZ (1) DZ2656A1 (is)
EA (1) EA002365B1 (is)
ES (1) ES2161548T3 (is)
GR (1) GR3037071T3 (is)
GT (1) GT199800166A (is)
HR (1) HRP20000327A2 (is)
HU (1) HUP0100272A3 (is)
ID (1) ID24524A (is)
IL (1) IL135713A0 (is)
IS (1) IS5453A (is)
MA (1) MA26568A1 (is)
NO (1) NO20002164L (is)
OA (1) OA11379A (is)
PA (1) PA8462301A1 (is)
PE (1) PE135399A1 (is)
PL (1) PL340643A1 (is)
PT (1) PT1032424E (is)
SK (1) SK7222000A3 (is)
TN (1) TNSN98211A1 (is)
TR (1) TR200001451T2 (is)
UA (1) UA57811C2 (is)
UY (1) UY25258A1 (is)
WO (1) WO1999026659A1 (is)
YU (1) YU30700A (is)
ZA (1) ZA9810636B (is)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536410A (ja) * 1999-02-12 2002-10-29 ノボ ノルディスク アクティーゼルスカブ 肥満の治療又は予防もしくは食欲の調節を目的とした薬学的組成物の製造におけるピロリジン誘導体の使用
EP1741445B1 (en) 2000-01-21 2013-08-14 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2002098429A1 (en) * 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7674913B2 (en) 2003-11-12 2010-03-09 Phenomix Corporation Heterocyclic boronic acid compounds
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2006017292A1 (en) 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
WO2006055462A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CA2622608C (en) 2005-09-14 2014-08-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
EP2046753A2 (en) 2006-07-06 2009-04-15 Brystol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP2010524953A (ja) 2007-04-17 2010-07-22 ブリストル−マイヤーズ スクイブ カンパニー 縮合ヘテロ環１１−β−ヒドロキシステロイドデヒドロゲナーゼＩ型阻害剤
PE20090213A1 (es) 2007-05-04 2009-02-28 Bristol Myers Squibb Co Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos
WO2008137435A1 (en) 2007-05-04 2008-11-13 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
EA018709B1 (ru) 2007-07-17 2013-10-30 Бристол-Маерс Сквибб Компани Пиридоновые агонисты сопряженного с g-белком рецептора gpr119
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
SI2531501T1 (sl) 2010-02-03 2014-04-30 Takeda Pharmaceutical Company Limited Inhibitorji kinaze-1, ki regulirajo signal apoptoze
MX2012011460A (es) 2010-04-08 2012-11-23 Squibb Bristol Myers Co Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119.
ES2559209T3 (es) 2010-04-14 2016-02-11 Bristol-Myers Squibb Company Nuevos activadores de la glucocinasa y métodos de uso de los mismos
EA201270778A1 (ru) 2010-05-06 2013-04-30 Бристол-Майерс Сквибб Компани Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
RU2013135224A (ru) 2011-01-20 2015-03-10 Бионевиа Фармасьютикалс Инк. Композиции с модифицированным высвобождением эпалрестата или его производных и способы их использования
EP2850073B1 (en) 2012-05-16 2017-07-19 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
US9580422B2 (en) 2013-10-22 2017-02-28 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2018017910A1 (en) 2016-07-22 2018-01-25 Bristol-Myers Squibb Company Glucokinase activators and methods of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4825448A (en) * 1986-08-07 1989-04-25 International Mobile Machines Corporation Subscriber unit for wireless digital telephone system
DE3889326D1 (de) * 1988-05-27 1994-06-01 Itt Ind Gmbh Deutsche Korrekturschaltung für ein digitales Quadratur-Signalpaar.
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
EP0832066B1 (en) * 1995-06-06 2001-09-12 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
CA2342471C (en) * 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates

Also Published As

Publication number Publication date
OA11379A (en) 2004-01-28
UA57811C2 (uk) 2003-07-15
DE69801680D1 (de) 2001-10-18
NO20002164D0 (no) 2000-04-27
EA002365B1 (ru) 2002-04-25
KR20010032300A (ko) 2001-04-16
HRP20000327A2 (en) 2001-02-28
GR3037071T3 (en) 2002-01-31
PE135399A1 (es) 2000-01-15
UY25258A1 (es) 2000-12-29
ATE205403T1 (de) 2001-09-15
AP9801401A0 (en) 1998-12-31
EP1032424A1 (en) 2000-09-06
KR20010032304A (ko) 2001-04-16
PA8462301A1 (es) 2000-05-24
WO1999026659A1 (en) 1999-06-03
DE69801680T2 (de) 2002-02-07
ID24524A (id) 2000-07-20
KR100661214B1 (ko) 2006-12-26
ZA9810636B (en) 2000-05-22
GT199800166A (es) 2000-04-19
TR200001451T2 (tr) 2002-06-21
SK7222000A3 (en) 2001-09-11
PL340643A1 (en) 2001-02-12
TNSN98211A1 (fr) 2005-03-15
EP1032424B9 (en) 2004-10-06
AR016423A1 (es) 2001-07-04
MA26568A1 (fr) 2004-12-20
CN1279617A (zh) 2001-01-10
EA200000433A1 (ru) 2000-12-25
CA2310069A1 (en) 1999-06-03
BG104435A (bg) 2001-01-31
HUP0100272A2 (hu) 2001-06-28
JP2002504478A (ja) 2002-02-12
HUP0100272A3 (en) 2002-11-28
EP1032424B1 (en) 2001-09-12
IL135713A0 (en) 2001-05-20
DZ2656A1 (fr) 2003-03-22
BR9814698A (pt) 2000-10-03
DK1032424T3 (da) 2001-11-19
YU30700A (sh) 2002-12-10
AU733304B2 (en) 2001-05-10
ES2161548T3 (es) 2001-12-01
AU9555898A (en) 1999-06-15
NO20002164L (no) 2000-07-19
PT1032424E (pt) 2001-12-28
AP911A (en) 2000-12-07

Similar Documents

Publication Publication Date Title
IS5453A (is) Samsetning af aldósa redúktasa lata og glýkógen fosfórýlasa lata
DK0969846T3 (da) Sammensætninger og fremgangsmåder til reduktion af okulær hypertension
DK1064298T3 (da) Inhibitorer af caspaser
DK0748782T3 (da) Cementeringssammensætninger og anvendelse af sådanne sammensætninger i cementering af olie- eller tilsvarende borehuller
DK1696124T3 (da) Kombination af kammer og stempel
DK1100459T3 (da) Sammensætning af skummende olie og dens anvendelse
MA26668A1 (fr) ACTIVATEURS DE hPPARy ET hPPARa
FI974436A0 (fi) Substituoituja N-(indoli-2-karbonyyli)-glysiiniamideja ja -johdannaisia glykogeenifosforylaasi-inhibiittoreina
NO20006488D0 (no) Sammensetning og anvendelse
ATE249191T1 (de) Kosmetische tensid zusammensetzung sowie ihre verwendung
NO994216D0 (no) Sementsammensetninger og bionedbrytbare dispergeringsmidler derfor
NO993217L (no) Broenntetningssammensetninger og fremgangsmåter
IL141763A0 (en) Assembly of panels and jointing elements
NO20001323D0 (no) Dipeptid-apoptose inhibitorer og deres anvendelse
DK1047450T3 (da) Kombinationer af ACE-inhibitorer og MMP-inhibitorer
DK1112003T3 (da) Ny sammensætning og anvendelse
DK1060147T3 (da) Afbindingsforsinkende systemer og anvendelse ved oliebrøndscementering
ATE274024T1 (de) Sauerstoffabsorbierende zusammensetzung und ihre anwendungsmethode
NO986174L (no) Triazinderivater og anvendelse derav
EP1379633A4 (en) ENZYMATIC CHANGE OF SEEDS VAN PLANTAGO PSYLLIUM
AU1522400A (en) Substituted pyrimidine compositions and methods of use
ID27987A (id) Komposisi-komposisi peroral levosimendan pelepasan terkontrol
PT1392670E (pt) Derivados substituidos de c-furan-2-il-metilamina e c-tiofen-2-il-metilamina
DK1272456T3 (da) Angioneseinhibitorer på basis af hydrazid og alkoxyamid
DK1512685T3 (da) Imidazonaphthyridiner og deres anvendelse til induktion af cytokinbiosyntese